WEBULL
News
SXTP
0.8299
+1.20%
0.0098
Geoffrey S. Dow, President and CEO, Acquires Common Shares of 60 Degrees Pharmaceuticals Inc
Reuters · 10h ago
Weekly Report: what happened at SXTP last week (1208-1212)?
Weekly Report · 1d ago
CEO Makes Bold Move with Major Stock Purchase in 60 Degrees Pharmaceuticals!
TipRanks · 4d ago
Geoffrey S. Dow, President and CEO, Acquires Common Shares of 60 Degrees Pharmaceuticals Inc
Reuters · 4d ago
60 Degrees Pharma To Expand ARAKODA Sales And Marketing, Adding Reps, GoodRx Partnership And Enhanced Digital Campaign
Benzinga · 5d ago
60 Degrees Pharmaceuticals expanding Arakoda sales and marketing in 2026
TipRanks · 5d ago
60 DEGREES PHARMACEUTICALS INC - TO ADD CLINICAL SITES FOR BABESIOSIS TRIALS
Reuters · 5d ago
Weekly Report: what happened at SXTP last week (1201-1205)?
Weekly Report · 12/08 10:23
Weekly Report: what happened at SXTP last week (1124-1128)?
Weekly Report · 12/01 10:18
Dick's Sporting Goods To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday
Benzinga · 11/28 13:35
60 Degrees Pharm Is Maintained at Buy by Ascendiant Capital
Dow Jones · 11/28 11:09
60 Degrees Pharm Price Target Cut to $2.80/Share From $3.00 by Ascendiant Capital
Dow Jones · 11/28 11:09
Ascendiant Capital Maintains Buy on 60 Degrees, Lowers Price Target to $2.8
Benzinga · 11/28 10:57
Weekly Report: what happened at SXTP last week (1117-1121)?
Weekly Report · 11/24 10:23
60 Degrees announces central site for B-FREE study open for patient enrollment
TipRanks · 11/21 13:15
60 Degrees Pharma Says Central Study Site For B-FREE Chronic Babesiosis Study Is Open For Patient Enrollment At Mount Sinai Icahn School Of Medicine
Benzinga · 11/21 13:06
60 DEGREES PHARMACEUTICALS ANNOUNCES CLINICAL SITE NOW OPEN FOR PATIENT ENROLLMENT FOR THE B-FREE CHRONIC BABESIOSIS STUDY AT MOUNT SINAI ICAHN SCHOOL OF MEDICINE
Reuters · 11/21 13:01
60 Degrees Pharmaceuticals Faces Financial Challenges Amid Growth Efforts
TipRanks · 11/18 04:05
Weekly Report: what happened at SXTP last week (1110-1114)?
Weekly Report · 11/17 10:23
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
TipRanks · 11/17 07:30
More
Webull provides a variety of real-time SXTP stock news. You can receive the latest news about 60 degrees pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SXTP
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.